» Articles » PMID: 35044626

Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of C-Fos and P70S6K Signaling Pathway

Overview
Journal Mol Neurobiol
Date 2022 Jan 19
PMID 35044626
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown that the heteromer composed by the dopamine D3 receptor (D3R) and the nicotinic acetylcholine receptor (nAChR) (D3R-nAChR heteromer) is expressed in dopaminergic neurons, activated by nicotine and represents the molecular unit that, in these neurons, contributes to the modulation of critical events such as structural plasticity and neuroprotection. We now extended this study by investigating the D3R-nAChR heteromer properties using various cell models such as transfected HEK293 cells, primary cultures of mouse dopaminergic neurons and human dopaminergic neurons derived from induced pluripotent stem cells.We found that the D3R-nAChR heteromer is the molecular effector that transduces the remodeling properties not only associated with nicotine but also with D3R agonist stimulation: neither nAChR nor D3R, in fact, when express as monomers, are able to elicit these effects. Moreover, strong and sustained activation of the PI3K-ERK1/2/Akt pathways is coupled with D3R-nAChR heteromer stimulation, leading to the expression of the immediate-early gene c-Fos and to sustained phosphorylation of cytosolic p70 ribosomal S6 kinase (p70S6K), critical for dendritic remodeling. By contrast, while D3R stimulation results in rapid and transient activation of both Erk1/2 and Akt, that is PI3K-dependent, stimulation of nAChR is associated with persistent activation of Erk1/2 and Akt, in a PI3K-independent way. Thus, the D3R-nAChR heteromer and its ability to trigger the PI3K-ERK1/2/Akt signaling pathways may represent a novel target for preserving dopaminergic neurons healthy and for conferring neuronal protection against injuries.

Citing Articles

The Neuroanatomy of Induced Pluripotent Stem Cells: In Vitro Models of Subcortical Nuclei in Neurodegenerative Disorders.

Galgani A, Scotto M, Giorgi F Curr Issues Mol Biol. 2024; 46(9):10180-10199.

PMID: 39329959 PMC: 11430477. DOI: 10.3390/cimb46090607.


Blockade of dopamine D3 receptors improves hippocampal synaptic function and rescues age-related cognitive phenotype.

Tropea M, Melone M, Li Puma D, Vacanti V, Aceto G, Bandiera B Aging Cell. 2024; 23(11):e14291.

PMID: 39236310 PMC: 11561665. DOI: 10.1111/acel.14291.


Nicotinic receptors in airway disease.

Borkar N, Thompson M, Bartman C, Khalfaoui L, Sine S, Sathish V Am J Physiol Lung Cell Mol Physiol. 2023; 326(2):L149-L163.

PMID: 38084408 PMC: 11280694. DOI: 10.1152/ajplung.00268.2023.


Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders.

Koyya P, Kumar Manthari R, Pandrangi S CNS Neurol Disord Drug Targets. 2023; 23(3):353-366.

PMID: 37287291 PMC: 11348470. DOI: 10.2174/1871527322666230607110617.


G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2.

Bono F, Tomasoni Z, Mutti V, Sbrini G, Kumar R, Longhena F Biomolecules. 2023; 13(3).

PMID: 36979407 PMC: 10046256. DOI: 10.3390/biom13030473.

References
1.
Wan L, Su L, Xie Y, Liu Y, Wang Y, Wang Z . Protein receptor for activated C kinase 1 is involved in morphine reward in mice. Neuroscience. 2009; 161(3):734-42. DOI: 10.1016/j.neuroscience.2009.03.064. View

2.
Mueller D, Chapman C, Stewart J . Amphetamine induces dendritic growth in ventral tegmental area dopaminergic neurons in vivo via basic fibroblast growth factor. Neuroscience. 2005; 137(3):727-35. DOI: 10.1016/j.neuroscience.2005.09.038. View

3.
Kriks S, Shim J, Piao J, Ganat Y, Wakeman D, Xie Z . Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011; 480(7378):547-51. PMC: 3245796. DOI: 10.1038/nature10648. View

4.
Strange P . Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 2001; 53(1):119-33. View

5.
Bono F, Mutti V, Fiorentini C, Missale C . Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection. Biomolecules. 2020; 10(7). PMC: 7407647. DOI: 10.3390/biom10071016. View